Compare CVKD & MRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVKD | MRM |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 15.8M |
| IPO Year | 2023 | 2020 |
| Metric | CVKD | MRM |
|---|---|---|
| Price | $9.94 | $2.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 28.8K | ★ 85.7K |
| Earning Date | 11-10-2025 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $55,915,220.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $49.67 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $8.12 | $0.34 |
| 52 Week High | $22.90 | $4.45 |
| Indicator | CVKD | MRM |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 59.26 |
| Support Level | $8.12 | $2.02 |
| Resistance Level | $11.58 | $2.16 |
| Average True Range (ATR) | 0.88 | 0.08 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 46.06 | 96.43 |
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.